New York-based psychedelic biotechnology company Gilgamesh Pharmaceuticals raised USD 39 million in a Series B funding round led by Prime Movers Lab with participation from Alumni Ventures, Palo Santo, and Negev Capital, among others.
The funding will be used to initiate Phase I/Ib safety and efficacy studies for the company’s lead programs GM-1020 and GM-2505 which are reportedly faster and less hallucinogenic compared to other psychedelic drugs being developed.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.